Company profile: Defence Therapeutics
1.1 - Company Overview
Company description
- Provider of biopharmaceutical innovations leveraging Accum™ technology, a drug delivery platform that enhances delivery of therapeutic agents to target cells to improve efficacy for cancer and infectious diseases. Offerings include cancer therapeutics, vaccine development for infectious diseases and cancers, antibody-drug conjugates, AccuTOX, and the ARM-002 anti-cancer vaccine shown effective in pre-clinical trials.
Products and services
- Accum™ Technology: A custom-engineered drug delivery platform that enhances therapeutic agent transport into target cells, boosting treatment efficacy against cancer and infectious diseases
- Vaccine Development: Immunology-optimized programs that create vaccines for infectious diseases and cancers, leveraging Accum™ for enhanced antigen presentation and stronger immune response
- Cancer Therapeutics: Targeted-delivery programs developing treatments for various cancers that use Accum™ to improve drug localization to malignant cells and overall therapeutic efficacy
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Defence Therapeutics
PharmaSeek
HQ: United States
Website
- Description: Provider of consulting and training solutions for clinical research sites, helping institutions, investigators, and independent sites decrease study start-up timelines by assuming administrative burdens of research management, including study identification, contract and budget negotiation, coverage analysis, and financial management.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PharmaSeek company profile →
SFJ Pharmaceuticals
HQ: United States
Website
- Description: Provider of strategic funding and joint-development partnerships, offering resources to accelerate clinical development and pharmaceutical asset approval, including trial design and execution; risk capital and expertise to support regulatory approvals across regions; and global clinical development resources for expedited approvals and lifecycle management.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SFJ Pharmaceuticals company profile →
Alpex
HQ: Switzerland
Website
- Description: Provider of research and development and production of orally dispersible tablets (ODT), also known as fast melt, and effervescent tablets. Offers a unique proprietary covering ODT technology, supported by high production capacity and advanced R&D technologies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alpex company profile →
Yposkesi
HQ: France
Website
- Description: Provider of CDMO services for gene and cell therapy, including cGMP manufacturing of AAV and lentiviral vectors (clinical and commercial batches), upstream and downstream bioprocess development, analytical development with assay qualification and validation, cGMP fill & finish, regulatory support, and the LentiSure platform to optimize yields, productivity, and transduction efficiency.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Yposkesi company profile →
Presidio Medical
HQ: United States
Website
- Description: Provider of a transformational neuromodulation platform and ULF Neuromodulation Therapy, which uses ultra low frequency current waveforms to inhibit pain signals; shown effective in clinical trials for chronic pain without causing paresthesia, enabling remedies for disorders affecting neuronal activity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Presidio Medical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Defence Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Defence Therapeutics
2.2 - Growth funds investing in similar companies to Defence Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Defence Therapeutics
4.2 - Public trading comparable groups for Defence Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →